Herb Research Foundation
"Improving world health and well being through herbs"

Kava

(Piper methysticum)

 

All articles are $20. Click Review Order button below
to view what you have selected and make any adjustments

Review Order

Backhauss C, Krieglstein J. Extract of kava (Piper methysticum) and its methysticin constituents protect brain tissue against ischemic damage in rodents. European Journal of Pharmacology 1992; 215: 265-269.

Brüggemann VF, Meyer HJ. The analgesic effects of the kava constituents dihydrokavain (DHK) and dihydromethysticin (DHM) [German]. Arzneim-Forsch 1963; 13: 407-409. (German paper with English summary)

Davies LP, Drew CA, Duffield P, et al. Kava pyrones and resin: studies on GABA-A, GABA-B, and benzodiazepine binding sites in rodent brain. Pharmacology and Toxicology 1992; 71: 120-126.

Gleitz J, Beile A, Peters T. Kavain inhibits veratridine-activated voltage-dependent Na+-channels in synaptosomes prepared from rat cerebral cortex. Neuropharmacology 1995; 34(9): 1133-1138.

Heinze H. Effects of oxazepam and an extract of kava roots (Piper methysticum) on event-related potentials in a word recognition test. Pharmacoelectroencephalography 1993; 27: 46-53

Heinze HJ, Münthe TF, Steitz J, et al. Pharmacopsychological effects of oxazepam and kava-extract in a visual search paradigm assessed with event-related potentials. Pharmacopsychiat 1994; 27: 224-130.

Holm E. Studies on the profile of neurophysiological effects of D,L-Kavain: cerebral sites of action and sleep-wakefulness-rhythm in animals [German]. Arzneim--Forsch/Drug Res 1991; 41(7): 673-683. (German paper with English summary).

Jamieson DD, Duffield PH. The antinociceptive actions of kava components in mice. Clinical and Experimental Pharmacology and Physiology 1990; 17: 495-508.

Lehmann E, Kinzler E, Friedemann J, et al. Efficacy of a special kava extract (Piper methysticum) in patients with states of anxiety, tension, and excitedness of non-mental origin a double blind placebo-controlled study of four weeks treatment. Phytomedicine 1996; III(2): 113-119.

Lehmann E, Klieser E, Klimke A, et al. The efficacy of cavain in patients suffering from anxiety. Pharmacopsychiat 1989; 22: 258-262.

Lindenberg VD, Pitule-Schödel H. D,L-Kavain in comparison with Oxazepam in anxiety states: double blind clinical trial [German]. Fortschritte der Therapie 1990; 108(2): 31-34. (German with English summary).

Münte TF, Heinze HJ, Matzke M, et al. Effects of oxazepam and an extract of kava roots (Piper methysticum) on event-related potentials in a word recognition task. Neuropsychobiology 1993; 27: 46-53.

Schulz H, Jobert M, Hübner WD.The quantitative EEG as a screening instrument to identify sedative effects of single doses of plant extracts in comparison with diazepam. Phytomedicine 1998; 5(6): 449-458.

Seitz U, Schüle A, Gleitz J. [3H]-Monoamine uptake inhibition properties of kava pyrones. Planta Med 1997; 63: 548-549.

Singh YN. Effects of kava on neuromuscular transmission and muscle contractility. Journal of Ethnopharmacology 1983; 7: 267-276.

Volz H-P, Kieser M. Kava-kava extract WS 1490 versus placebo in anxiety disorders -- a randomized placebo-controlled 25-week outpatient trial. Pharmacopsychiat 1997; 30:1-5.